#direct-acting antivirals

Recent drug use along with unstable housing increased the risk of acquiring HCV again.

The burden of viral and nonviral liver disease remains high even in the setting of hepatitis C microelimination.

People with advanced fibrosis—not just cirrhosis—were at greater risk for hepatocellular carcinoma.

The program aims to expand testing, reduce drug costs and raise awareness of hepatitis C.

Cutting the duration of treatment also cut the likelihood of a cure.

Successful antiviral treatment partially turns back the clock on age acceleration.

The Grand Plan Study showed that a multidisciplinary program can produce a high cure rate with little loss to follow-up.

Even those with a history of heavy alcohol use who are currently abstinent have trouble receiving treatment.

Advocates are working to deliver medication directly to patients to combat this alarming decrease in care.

People treated with direct-acting antivirals had a lower risk for liver failure and liver cancer as well as much lower mortality.

The three-drug combination cured most people who had experienced previous treatment failure.

ReLink programs treated 19% of people who were brought back into HCV care after being lost to follow-up.

Current guidelines recommend antiviral treatment regardless of alcohol use.

Two thirds of people who currently use drugs completed treatment, and most of those were cured.

People who achieved SVR two or more years ago were less likely to develop hepatocellular carcinoma than those cured more recently.

People who recently used drugs were more likely to get HCV again after successful treatment.